Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

被引：23
|
作者：
Daver, Naval
Altman, Jessica K.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James K.
Smith, Catherine C.
Schiller, Gary J.
Bradley, Terrence
Tiu, Ramon V.
Hong, Wan-Jen
Tong, Bo
Qin, Qin
Dilley, Kimberley
Perl, Alexander E.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139705
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] A SYSTEMATIC REVIEW OF THE HUMANISTIC BURDEN OF FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Casamayor, M.
    Gubbels, L.
    Garnham, A.
    Shah, M., V
    VALUE IN HEALTH, 2020, 23 : S29 - S29
  • [32] ESTIMATION OF HEALTH STATE UTILITIES IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Cella, D.
    Qi, C. Z.
    Yang, H.
    Garnham, A.
    Shah, M., V
    VALUE IN HEALTH, 2020, 23 : S77 - S78
  • [33] Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
    Smith, Catherine C.
    Levis, Mark J.
    Perl, Alexander E.
    Hill, Jason E.
    Rosales, Matt
    Bahceci, Erkut
    BLOOD ADVANCES, 2022, 6 (07) : 2144 - 2155
  • [34] Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/ refractory FLT3mut acute myeloid leukemia
    Fu, Qiang
    Wang, Yunqi
    Liu, Hongtao
    Gao, Haitao
    Sun, Wei
    Jiang, Qian
    Jiang, Hao
    Liu, Kaiyan
    Huang, Xiaojun
    Tang, Feifei
    LEUKEMIA RESEARCH, 2024, 145
  • [35] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
    Alexander E. Perl
    Naoko Hosono
    Pau Montesinos
    Nikolai Podoltsev
    Giovanni Martinelli
    Nicki Panoskaltsis
    Christian Recher
    Catherine C. Smith
    Mark J. Levis
    Stephen Strickland
    Christoph Röllig
    Marco Groß-Langenhoff
    Wen-Chien Chou
    Je-Hwan Lee
    Hisayuki Yokoyama
    Nahla Hasabou
    Qiaoyang Lu
    Ramon V. Tiu
    Jessica K. Altman
    Blood Cancer Journal, 12
  • [36] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
    Perl, Alexander E.
    Hosono, Naoko
    Montesinos, Pau
    Podoltsev, Nikolai
    Martinelli, Giovanni
    Panoskaltsis, Nicki
    Recher, Christian
    Smith, Catherine C.
    Levis, Mark J.
    Strickland, Stephen
    Rollig, Christoph
    Gross-Langenhoff, Marco
    Chou, Wen-Chien
    Lee, Je-Hwan
    Yokoyama, Hisayuki
    Hasabou, Nahla
    Lu, Qiaoyang
    Tiu, Ramon, V
    Altman, Jessica K.
    BLOOD CANCER JOURNAL, 2022, 12 (05)
  • [37] Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia
    Wang, Jianxiang
    Jiang, Bin
    Li, Jian
    Liu, Ligen
    Du, Xin
    Jiang, Hao
    Hu, Jianda
    Yuan, Menghe
    Sakatani, Taishi
    Kadokura, Takeshi
    Takeuchi, Masato
    Izuka, Shunsuke
    Girshova, Larisa
    Tan, Jerome
    Bondarenko, Sergey N.
    Wong, Lily L. L.
    Khuhapinant, Archrob
    Martynova, Elena
    Hasabou, Nahla
    Tiu, Ramon V.
    BLOOD, 2021, 138
  • [38] Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
    Greco, Rosa
    Imbergamo, Silvia
    Pierdomenico, Elisabetta
    Di Camillo, Barbara
    Papayannidis, Cristina
    Todisco, Elisabetta
    Borlenghi, Erika
    Fracchiolla, Nicola
    Basilico, Claudia
    Fumagalli, Monica
    Zappasodi, Patrizia
    Turrini, Mauro
    Candoni, Anna
    Lunghi, Monia
    Musso, Maurizio
    Vetro, Calogero
    Guolo, Fabio
    Mannina, Donato
    Lico, Albana
    Scattolin, Anna Maria
    Nadali, Gianpaolo
    Crugnola, Monica
    Galimberti, Sara
    Marchesi, Francesco
    Metafuni, Elisabetta
    di Toritto, Tommaso Caravita
    Minotti, Clara
    Musto, Pellegrino
    Mancini, Valentina
    Riva, Marta
    Rizzo, Lorenzo
    Grillo, Giovanni
    Cairoli, Roberto
    BLOOD, 2024, 144 : 5188 - 5189
  • [39] Azacitidine and Venetoclax Followed By Sequential Gilteritinib Is an Effective Alternative in Very Frail Patients with FLT3-Mutated Acute Myeloid Leukemia
    Nedumannil, Rithin
    Matley, Chelsea
    Bajel, Ashish
    Levis, Mark J.
    Wei, Andrew H.
    BLOOD, 2024, 144 : 6060 - 6061
  • [40] The Frida Study: An Option for Mutated FLT3 Relapsed/Refractory Acute Myeloid Leukemia Patients with a Novel Iadademstat and Gilteritinib Combination Therapy
    Fathi, Amir T.
    Arevalo, Mabel
    Gutierrez, Sonia
    Molero, Antonieta
    Sacilotto, Natalia
    Limon, Ana
    Faller, Douglas, V
    BLOOD, 2022, 140 : 11755 - 11756
12345